Immunotherapy for recurrent malignant melanoma: Efficacy of BCG in prolonging the postoperative disease free interval and survival

J. U. Gutterman, S. P. Richman, C. M. McBride

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

In this report, the authors summarize updated results with adjuvant immunotherapy with bacillus Calmette-Guerin (BCG) for patients with recurrent malignant melanoma. This program was initiated in 1971.

Original languageEnglish (US)
Pages (from-to)359-362
Number of pages4
JournalRecent Results in Cancer Research
VolumeVol. 68
DOIs
StatePublished - 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunotherapy for recurrent malignant melanoma: Efficacy of BCG in prolonging the postoperative disease free interval and survival'. Together they form a unique fingerprint.

  • Cite this